```html

Quinine‑Associated Hemolytic Anemia

Overview

Quinine‑associated hemolytic anemia is a type of acquired hemolytic anemia that occurs when the drug quinine (or quinine‑containing products) triggers the immune system to destroy red blood cells (RBCs). The reaction is most often drug‑induced immune hemolytic anemia (DIIHA), a rare but serious condition.

Who it affects: The condition can affect anyone who takes quinine, but it is seen most frequently in adults ≥ 40 years old and in patients with a history of autoimmune disorders or prior exposure to quinine. Women appear slightly over‑represented, probably because they are more likely to use quinine‑containing “night‑time leg cramps” supplements.

Prevalence: DIIHA overall is estimated at 1–2 cases per million people per year. Quinine‑related cases make up roughly 10–15 % of those reports, translating to about 0.1–0.3 cases per million annually <sup>1</sup>. Because quinine is an over‑the‑counter medication in many countries, the true incidence may be under‑reported.

Symptoms

Symptoms arise from rapid destruction of RBCs (hemolysis) and can range from mild fatigue to life‑threatening shock. The most common signs include:

• Fatigue and weakness – due to reduced oxygen‑carrying capacity.
• Pallor – especially of the conjunctivae and nail beds.
• Jaundice – yellowing of the skin and sclera from elevated bilirubin.
• Dark urine (cola‑colored) – caused by hemoglobinuria.
• Back or flank pain – result of renal tubular irritation.
• Shortness of breath – especially on exertion.
• Rapid heart rate (tachycardia) – compensatory response to anemia.
• Fever and chills – may mimic an infection; often present when hemolysis is intense.
• Abdominal pain – can occur when bilirubin precipitates in the gallbladder.
• Gout‑type joint pain – excess uric acid from RBC breakdown.
• Signs of acute kidney injury – oliguria, swelling of ankles, or hypertension.

Symptoms typically appear **within hours to 2 weeks** after the first dose of quinine or after a dose increase.

Causes and Risk Factors

Mechanism of injury

Quinine can act as a hapten, binding to proteins on the RBC surface and forming a new antigenic complex. In susceptible individuals, the immune system produces IgG or IgM antibodies that target this complex, resulting in:

• Complement‑mediated intravascular hemolysis (IgM‑mediated).
• Extravascular hemolysis by splenic macrophages (IgG‑mediated).

The hemolysis is *immune* rather than due to direct toxicity, which means cessation of the drug usually halts the process.

Risk factors

• Prior quinine exposure – sensitization can develop after a single dose.
• Autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis) – higher baseline auto‑antibody production.
• History of other drug‑induced hemolysis (e.g., penicillin, α‑methyl‑dopa).
• G6PD deficiency – while G6PD deficiency typically causes non‑immune hemolysis, co‑administration of quinine can worsen the picture.
• High‑dose or chronic use – “night‑time leg cramp” supplements often contain 200 mg or more per tablet.
• Age > 50 years – immune dysregulation increases with age.

Diagnosis

Clinical suspicion

Any patient who develops acute hemolytic signs shortly after starting quinine should raise suspicion for DIIHA. A thorough drug history (including OTC and herbal products) is essential.

Laboratory tests

• Complete blood count (CBC) – shows anemia (low hemoglobin/hematocrit) with possible reticulocytosis.
• Reticulocyte count – elevated (>2 %) indicating bone‑marrow response.
• Lactate dehydrogenase (LDH) – markedly increased due to cell lysis.
• Haptoglobin – usually undetectable (consumed by free hemoglobin).
• Indirect bilirubin – rises as the liver processes excess heme.
• Urinalysis – positive for hemoglobin (dipstick) with no RBCs on microscopy (hemoglobinuria).
• Direct antiglobulin test (DAT or Coombs test) – positive for IgG and/or complement (C3) on RBCs; a key diagnostic hallmark of immune-mediated hemolysis.
• Serum creatinine & electrolytes – assess renal involvement.

Specialized testing

If the DAT is positive but the cause is unclear, specialized assays (e.g., drug‑dependent antibody testing) can be performed in reference laboratories, confirming quinine‑dependent antibodies <sup>2</sup>.

Imaging

Ultrasound of the abdomen may be ordered if jaundice is severe or if gallstones are suspected, but imaging is not required for diagnosis.

Treatment Options

Immediate steps

• Discontinue quinine immediately – removal of the offending drug stops antibody formation.
• Supportive care – intravenous fluids to maintain renal perfusion; monitor urine output.

Pharmacologic therapy

• Corticosteroids (e.g., prednisone 1 mg/kg/day) – often given for severe hemolysis; evidence is limited but they may dampen the immune response.
• Intravenous immunoglobulin (IVIG) – considered when rapid hemolysis persists despite steroids, especially in patients with high‑titer antibodies.
• Rituximab – a monoclonal anti‑CD20 antibody; reserved for refractory cases or when steroids/IVIG fail.
• Erythropoiesis‑stimulating agents (ESAs) – may be used in chronic anemia after the acute phase.

Transfusion

Red blood cell (RBC) transfusion is indicated for symptomatic anemia (Hb < 7 g/dL) or hemodynamic instability. Because antibodies are drug‑dependent, cross‑matching is usually straightforward once quinine is stopped. However, consult transfusion medicine for complex cases.

Renal management

Acute kidney injury (AKI) occurs in 10–20 % of severe cases. Management includes:

• Aggressive isotonic fluid administration.
• Loop diuretics if volume‑overloaded.
• Renal replacement therapy (dialysis) for refractory AKI or severe hyperkalemia.

Long‑term follow‑up

Repeat CBC, LDH, bilirubin, and renal labs weekly until stable, then monthly for 3–6 months. Most patients recover fully within 4–6 weeks after stopping quinine.

Living with Quinine‑Associated Hemolytic Anemia

Medication vigilance

• Never restart quinine or quinine‑containing products (including over‑the‑counter leg‑cramp tablets, tonic water, and some herbal mixes).
• Ask pharmacists to cross‑check prescriptions for quinine content.

Monitoring

• Keep a personal log of hemoglobin, bilirubin, and symptoms; share with your clinician.
• Set reminders for follow‑up labs—initially weekly, then monthly.

Nutrition & lifestyle

• Maintain adequate iron, folate, and vitamin B12 intake (leafy greens, legumes, fortified cereals).
• Hydrate aggressively (≥ 2 L/day) to protect kidneys.
• Avoid other hemolysis‑triggering drugs (e.g., sulfa antibiotics, dapsone) unless medically necessary.
• Balance activity: light aerobic exercise is fine, but avoid extreme exertion until hemoglobin stabilizes.

Psychosocial support

Experiencing a drug reaction can be anxiety‑provoking. Consider counseling, support groups for drug‑induced anemia, or patient advocacy organizations such as the American Hematology Society.

Prevention

• Limit quinine use – follow FDA guidance: quinine is approved only for treatment of uncomplicated malaria; “leg‑cramp” use is discouraged.
• Read labels – tonic water contains up to 83 mg quinine per liter; patients with prior reaction should avoid it.
• Allergy documentation – add “quinine‑induced hemolytic anemia” to your allergy list in every electronic health record.
• Physician awareness – inform your healthcare team of any prior hemolysis before starting new medications.
• Genetic screening – if you have G6PD deficiency, discuss alternative treatments with your doctor.

Complications

If the hemolysis is not promptly controlled, several serious complications may arise:

• Acute renal failure – hemoglobin casts damage renal tubules.
• Severe anemia – can lead to high‑output heart failure, angina, or syncope.
• Hyperbilirubinemia – may precipitate gallstone formation.
• Thromboembolic events – released free hemoglobin promotes platelet activation.
• Secondary infections – due to splenic sequestration and blood transfusions.
• Chronic hemolysis – rare, may transition to a persistent autoimmune hemolytic anemia requiring long‑term immunosuppression.

When to Seek Emergency Care

References

1. Barcellini, W., et al. “Drug‑induced immune hemolytic anemia.” Blood Reviews 2018;32(1):27‑36. PMCID: PMC3319384
2. Arndt, P. A., “Laboratory diagnosis of drug‑dependent hemolytic anemia.” Transfusion Medicine Reviews 2020;34(2):86‑94. PMCID: PMC6369978
3. Mayo Clinic. “Quinine side effects.” MayoClinic.org
4. U.S. Food & Drug Administration. “FDA Drug Safety Communication: Quinine for Leg Cramps.” 2023. FDA.gov
5. National Heart, Lung, and Blood Institute. “Hemolytic Anemia.” 2022. NIH.gov

```